Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Breast: Metastatic, Breast: Early Stage DiseaseNCT ID: NCT01982448
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-383
This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test Homologous Recombination Deficiency (HRD) assay can predict response to preoperative treatment.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center
Overall PI: Erica Mayer, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Nadine Tung, MD,
Beth Israel Deaconess Medical Center
Contacts: Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060